Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

NCT06177015 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer
Intermitent Anti-androgen Therapy

Interventions

DRUG: Darolutamide continuous
DRUG: Darolutamide intermittent

Sponsor

The First Affiliated Hospital with Nanjing Medical University